We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia (ALL). Expression of ASPP1 was significantly reduced in ALL and was dependent on hypermethylation of the ASPP1 gene promoter. Abnormal ASPP1 expression was associated with normal function of the tumor-suppressor gene TP53 in ALL. The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25% of cases with decreased mRNA expression. Methylation was significantly higher in adult ALL vs childhood ALL (32 vs 17%, P ¼ 0.03) and T-ALL vs B-ALL (50 vs 9%, P ¼ 0.001). Relapse rate (62 vs 44%, P ¼ 0.05) and mortality (59 vs 43%, P ¼ 0.05) were significantly higher in patients with methylated ASPP1. DFS and OS were 32.8 and 33.7% for patients with unmethylated ASPP1 and 6.1 and 9.9% for methylated patients (Po0.001 y Po0.02, respectively). On the multivariate analysis, methylation of the ASPP1 gene promoter was an independent poor prognosis factor in ALL patients. Our results demonstrate that decreased expression of ASPP1 in patients with ALL is due to an abnormal methylation of its promoter and is associated with a poor prognosis.
Introduction
TP53, a tumor-suppressor gene located in the short arm of chromosome 17, is the most frequently mutated gene in human cancer. The gene product is a 393 amino-acid nuclear phosphoprotein that regulates different cellular processes such as gene transcription, DNA synthesis, DNA repair, cell cycle arrest, senescence and apoptosis. Mutations of TP53 may result in an inhibition of protein function, which is associated with tumor progression and genetic instability (Caron de Fromentel and Soussi, 1992; Hollstein et al., 1994; Soussi et al., 1994) . Although 40-50% of human tumors have mutations on TP53, the percentage of mutations in patients with leukemia is significantly lower (less that 10%), suggesting that other mechanisms may be involved in the inability of p53 to induce apoptosis since p53 does not suppress tumor growth or induce apoptosis in tumors with wild-type TP53.
The recently described ASPP family of proteins comprised of ASPP1, ASPP2 and iASPP has been implicated in the apoptotic function of TP53 and p53 family members TP73L (p63) and TP73 (Bergamaschi et al., 2004) . Different studies have shown that ASPP1 and ASPP2 increase the apoptotic effect of p53 by inducing the transcription of proapoptotic genes such as BAX and PIG3 mediated by TP53, while they have no influence on the transcription of MDM2 and CDKN1A (p21, Cip1), which mediate p53-dependent cell cycle arrest (Samuels-Lev et al., 2001; Slee and Lu, 2003; Bergamaschi et al., 2004) . Transactivation of TP53-mediated transcription of proapoptotic genes mediated by ASPP1 and ASPP2 is completely abolished by increased expression of the evolutionary conserved TP53 inhibitor and third member of the ASPP family, iASPP (Bergamaschi et al., 2003) .
It has been hypothesized that in wild-type TP53 tumors, alterations of ASPP1 and/or ASPP2, can produce a selective advantage due to the lack of stimulation of apoptosis (Samuels-Lev et al., 2001; Slee and Lu, 2003; Bergamaschi et al., 2004) . Samuels-Lev et al. (2001) studied the mRNA expression levels of ASPP1 and ASPP2 in breast cancer samples with wildtype TP53, showing that the level of ASPP1 and ASPP2 mRNA was downregulated in 60 and 22.5% of samples, respectively (Samuels-Lev et al., 2001). Recently, Liu et al. (2004) have analyzed the mRNA expression levels of ASPP family members in three leukemia cell lines and Zhang et al. (2005) have studied the expression of iASPP mRNA in acute leukemias. These analyses have shown a downregulation of ASPP1 and an upregulation of iASPP mRNA levels, suggesting that alterations of ASPP could be an important step in the pathogenesis of hematological neoplasm (Liu et al., 2004; Zhang et al., 2005) .
Aberrant DNA methylation has been established as an essential and major epigenetic mechanism that participates in the regulation and inactivation of gene expression and induction of tumorigenesis (Bird, 2002; Esteller, 2002) . Several reports have shown abnormal hypermethylation in the promoter region of genes involved in cell cycle control, apoptosis, cell-cell adhesion and DNA repair in human leukemias and we have demonstrated that abnormal methylation of the promoter of a number of genes is common in patients with acute lymphoblastic leukemia (ALL) (RomanGomez et al., 2003 (RomanGomez et al., , 2004a Rossi et al., 2004) , which is associated with the inappropriate transcriptional silencing of these genes and represents an alternative mechanism to gene mutations and deletions.
The abnormal expression of members of the ASPP family in leukemic cell lines, the presence of a CpG island in the promoter region of ASPP1 and ASPP2 as well as the fact that abnormal methylation of the promoter of a number of genes is common in patients with ALL, led us to study the role of ASPP1, ASPP2, iASPP and their relation with TP53 in the pathogenesis of ALL. We have analyzed if expression of ASPP1 and ASPP2 is regulated epigenetically by abnormal promoter hypermethylation and whether this expression is associated with prognosis in patients with ALL.
Results
Regulation of ASPP1, ASPP2 and iASPP expression in tumor cell lines We initially examined the expression of ASPP1, ASPP2 and iASPP in a number of ALL cell lines by Q-RT-PCR. No ASPP1 expression was observed in Bprecursor ALL cell lines (MY, NALM-20 and TOM-1). A reduced expression was observed in two T-cell ALL cell lines (JOURKAT and MOLT-4), whereas the LOUCY T-ALL cell line showed normal levels of ASPP1 expression (Table 2 and Figure 1b) . Expression of ASPP2 and iASPP was not altered in ALL (data not shown).
As the promoters of ASPP1 and ASPP2 contain a typical CpG island showing >60% C þ G content and an observed-overexpected CpG frequency of >0.6 we decided to analyze their methylation status. By MSP, the ASPP1 promoter was revealed to be highly methylated in ALL cell lines lacking ASPP1 expression (TOM-1, NALM-20 and MY) (Figure 1a) , which was clearly in contrast with the lack of ASPP1 promoter methylation observed in normal cells as well as CML, breast and lung carcinoma-derived cell lines (data not shown). Methylation of the ASPP1 promoter was further demonstrated by bisulfite sequencing of different clones obtained after cloning MSP products, which showed a complete concordance with MSP results (Figure 1c ). While bone marrow DNA from a healthy donor showed a nonmethylated ASPP1 promoter, sequencing of human male genomic DNA universally methylated and NALM-20 (ASPP1 promoter hypermethylation by MSP and lack of ASPP1 expression by PCR) showed a complete methylation throughout the entire region analyzed. In ALL-derived LOUCY cell line, which had a nonmethylated ASPP1 promoter by MSP and normal ASPP1 mRNA expression, sequencing analysis revealed an unmethylated pattern with methylation of only a few individual CpG sites (Figure 1c) .
Exposure of ALL cell lines to the demethylating agent 5-Aza-2 0 -deoxycytidine restored expression of ASPP1 mRNA in cell lines that showed hypermethylation of the ASPP1 promoter such as MY, NALM-20 and TOM-1 (Figure 1d ) but had no effect on ASPP1 mRNA expression in nonmethylated ALL-derived JOURKAT, MOLT-4 and LOUCY cell lines. Furthermore, treatment of ALL-derived NALM-20 cells with 2 mM of 5-Aza-2 0 -deoxycytidine was associated with the presence of both the methylated (ASPP1-1/ASPP1-2) and unmethylated (ASPP1-3/ASPP1-4) MSP product while MSP analysis performed with DNA of NALM-20 cells treated with 4 mM of 5-Aza-2 0 -deoxycytidine showed only the methylated MSP product (Figure 1e) , along with the upregulation of ASPP1 mRNA. These results indicate that hypermethylation is a major mechanism through which ASPP1 expression is silenced in ALL cells ( Figure 1 and Table 2 ). As expected, from the ASPP2 expression analysis, we did not find an abnormal methylation pattern of the ASPP2 promoter (data not shown).
While TOM-1 and MY cell lines presented both the methylated and unmethyated allele, the NALM-20 cell line had only the methylated form. To determine whether complete lack of ASPP1 expression in NALM-20 was due to hypermethylation of both promoters or to other mechanisms we analyzed the possibility of gene deletions by Fluorescence in situ hybridization (FISH). FISH analysis using 1 BAC covering the ASPP1 gene demonstrated that a deletion of ASPP1 was present in NALM-20 and in a subpopulation of TOM-1 cell line, suggesting that complete lack of expression of ASPP1 in the NALM-20 cell line can be due to methylation of one allele and deletion of the other one (Figure 2 ).
Analysis of TP53 mutation, deletion and promoter methylation in ALL cell lines Although TP53 is frequently mutated in a number of tumors this is not the case in ALL where the frequency of TP53 mutations is lower than 10%. Abnormal expression of ASPP1, in the context of functional TP53 would suggest a potential role for ASPP1 in ALL ASPP1 expression and regulation in ALL X Agirre et al resistance to apoptosis. So, to determine whether TP53 was functional in our ALL cells lines (TOM-1, NALM-20, MY, LOUCY and TANOUE cell lines) we examined the presence of mutation or deletion of TP53 or abnormal methylation of its promoter region. Mutation analysis by DGGE showed an aberrant electrophoretic pattern only in the LOUCY cell line that did not present an aberrant methylation of the ASPP1 promoter Figure S1 ). Sequencing of TP53 exon 8 of the LOUCY cell line showed that this aberrant electrophoretic pattern corresponds to a previously described V272 M (GTG-ATG) missense mutation in exon 8 (Supplementary Figure S1B) . Abnormal methylation was not detected either in the CpG dinucleotide (Hpa II/Msp I) or in the CC(A/T)GG (Eco RII/Bst NI) motifs in any of the ALL-derived cell lines (Supplementary Figure S2 ). FISH analysis performed using a RPCI-11 199F11 BAC clone, that covers TP53 gene, and one alphoide probe, that covers the chromosome 17 centromere, showed a normal hybridization pattern (two red -RPCI-11 199F11 BAC clone -and two green signalschromosome 17 centromere-) in TOM-1 and deletion of one allele of TP53 in the NALM-20 cell line (one red and two green signals). Two different clones were identified in the TANOUE and LOUCY cell lines. While the most frequent clone in the TANOUE cell line did not show an abnormal signal, a second clone had three red and three green signals that corresponded to three complete chromosomes 17. Similarly, we found one clone with four red and four green signals and a second one with three red and four green signals in the LOUCY cell line, corresponding to a deletion of one of the four TP53 alleles present in this cell clone (Supplementary Figure S3 ).
Methylation and downregulation of ASPP1 mRNA is associated with poor prognosis in patients with B and T-ALL In order to determine the prognostic value of ASPP1 in patients with ALL, we analyzed the mRNA expression and promoter methylation in a group of 180 patients. ASPP1 methylation was detected at diagnosis in 25% (45/180) of patients with adult or childhood ALL of all the FAB subtypes. In all these patients a downregulation of ASPP1 expression was observed. In contrast, decreased ASPP1 expression was detected in only 18 of 135 ALL patients with an unmethylated promoter (13%).
As shown in Table 1 , aberrant ASPP1 methylation was more frequently observed in adults than in children (32 vs 17%, P ¼ 0.03) and also in T-cell ALL than in precursor-B ALL (50 vs 9%, P ¼ 0.001). Other clinical and laboratory features did not differ significantly between methylated and nonmethylated patients. Poorrisk cytogenetic or molecular events, risk groups according to both NCI or 'Programa para el estudio y tratamiento de las hemopatias malignas' (PETHEMA) classifications, good risk features (hyperdiploidy and TEL-AML1 fusion), type of PETHEMA protocol administered and number of patients who received stem cell transplantation were similarly distributed between the two groups defined by ASPP1 promoter methylation. Separate analysis of adult and childhood ALL patients gave the same results as the global series. Table 1 details the relapse history, CR rates and mortality for patients who exhibited ASPP1 methylation and the equivalent data for patients with the normal ASPP1 gene. CR rates of patients with the normal and methylated ASPP1 gene were 91 and 85%, respectively, accounting for an 88% overall CR rate. This suggests that methylation of the ASPP1 gene promoter did not correlate with response to remission induction therapy. However, patients with abnormal methylation of the ASPP1 promoter had a higher relapse (62 vs 44%, P ¼ 0.05) and mortality rate (59 vs 43%, P ¼ 0.05) than nonmethylated patients.
We finally analyzed DFS among patients who achieved CR according to ASPP1 methylation (Table 2 ). Estimated DFS rates at 6 years were 32.8 and 6.1% for normal and methylated patients, respectively (P ¼ 0.001) (Figure 3a ). Among children with unmethylated ASPP1 promoter, the 6 years DFS was 45.4% contrasting with 13.9% for children with hypermethylated ASPP1 promoter (P ¼ 0.006, Figure 3b ). Among adult ALL patients, the 3-years DFS was 0% for methylated cases and 35.7% for unmethylated cases (P ¼ 0.1, Figure 3c ). The actuarial OS calculated for all leukemic patients was 33.7 and 9.9% at 10 years for cases with the unmethylated and hypermethylated ASPP1 gene promoter, respectively (P ¼ 0.02, Figure 4a ). Among childhood ALL patients, the 10-years OS was 34.8% for methylated cases and 47.8% for unmethylated cases (P ¼ 0.08, Figure 4b) .
A multivariate analysis of potential prognostic factors (including the type of PETHEMA protocol applied) demonstrated that methylation of the ASPP1 gene Figure 2 FISH analysis of ASPP1 gene in NALM-20 and TOM-1 cell lines. RP11-73M18 probe that covers the ASPP1 was labeled with Spectrum Orange s (red signal), RP11-600F24 probe centromeric to ASPP1 with Spectrum Green s (green signal), and alphoide probe located in chromosome 14 and 22 centromeres with DEAC (light blue signal).
ASPP1 expression and regulation in ALL X Agirre et al promoter was an independent prognostic factor for DFS in the global series and also in childhood ALL (Table 3) .
Discussion
The recent identification of ASPP proteins as key regulators of p53 function has significantly contributed to understanding why despite normal p53 function, some tumor cells are able to escape from p53-induced apoptosis after DNA damage (Samuels-Lev et al., 2001; Bergamaschi et al., 2004) . Although recent studies have (Liu et al., 2004; Zhang et al., 2005) , our results describe for the first time that a significant percentage of patients with ALL have a decreased expression of ASPP1; that lack of expression is due to hypermethylation of the gene promoter and, more importantly, that hypermethylation and downregulation of ASPP1 expression is, significantly and independently of other prognostic factors, associated with poor prognosis with a reduced DFS and OS both in children and adult ALL. The initial isolation of ASPP1 and ASPP2 proteins was performed based on two hybrid screening systems using p53 and bcl-2 as baits (Iwabuchi et al., 1994; Naumovski and Cleary, 1996) . These studies identified two proteins 53BP2 and Bbp that are now recognized as truncated forms of ASPP2 (C-terminal 529 amino acids and the truncation of 123 amino acid at the N-terminal, respectively). The fact that the initial studies were performed with the truncated forms further added some confusion to their physiological role as the results were sometimes contradictory (Gorina and Pavletich, 1996; Iwabuchi et al., 1998; Lopez et al., 2000; Mori et al., 2000; Ao et al., 2001 ). However, a more detailed and clear description of their structure and function has only recently been performed along with isolation of the third member of the family, an inhibitor of p53 function iASPP (Samuels- Lev et al., 2001; Bergamaschi et al., 2003) . The relevance of these proteins in tumorigenesis stems from the fact that they regulate p53 function by transactivating p53 transcription of proapoptotic genes and also by directly stimulating the proapoptotic activity of p53. Abnormal expression of ASPP members has been described in breast cancer where ASPP1 and ASPP2 are downregulated in 60 and 23% of tumors, respectively (Samuels-Lev et al., 2001) . Interestingly, downregulation of ASPP1 and ASPP2 is more frequently detected in breast cancer samples from patients with unmutated p53 further substantiating how tumors are able to arise even in the presence of wild-type p53. In lung cancer cell lines, downregulation of 53BP2 has also been associated with resistance to chemotherapyinduced apoptosis (Mori et al., 2000) .
Along the same lines, we have described that 38% of patients with newly diagnosed ALL show a downregulation of ASPP1 and have demonstrated that expression of ASPP1 is controlled epigenetically by methylation of gene promoter both in ALL cell lines and also in patient's primary cells. However, no promoter hypermethylation was observed in other type of tumors such as CML, lung or breast cancer. As we have described previously, methylation controls the expression of a number of genes in patients with ALL where we have demonstrated that the methylation profile is associated with disease prognosis and survival (RomanGomez et al., 2004b) . Besides prognostic significance, methylation of ASPP1 could also be especially relevant in that it could help to explain why tumors with normal p53 have a selective advantage as cells are resistant to apoptosis. Although we did not perform functional studies in our cell lines, lack of p53 mutation, methylation and deletion in cell lines with otherwise abnormal ASPP1 expression indicates that resistance to apoptosis in these cell lines might be dependent on ASPP1. One exception deserves further comment: the NALM-20 cell line had a total lack of expression of ASPP1 and also a lack of amplification of the unmethylated allele, unlike other cell lines such as TOM-1 in which both the unmethylated and methylated allele were amplified by PCR (Figure 1a) . FISH analysis of ASPP1 in NALM-20 demonstrated that there was a deletion of ASPP1 suggesting that at least in this cell line, complete absence of ASPP1 is dependent on deletion of one allele and methylation of the other. Liu et al. (2005) described in three cell lines from breast cancer and hepatocarcinoma that downregulation of ASPP1 and ASPP2 was associated with abnormal methylation of their promoters. We did not find an abnormal methylation of the ASPP2 promoter either in ALL or CML cells, although ASPP1 was hypermethylated in a significant percentage of patients with ALL. Other mechanisms of ASPP1 and ASPP2 silencing may exist. Although so far mutations of either of the two genes have not been described, we observed in CML cells from patients that a significant percentage of them have a reduced expression of ASPP1 that is not associated with hypermethylation of the promoter, suggesting that other mechanisms may be involved in the regulation of ASPP proteins (unpublished observations).
In conclusion, our results suggest a role for ASPP1 in the pathogenesis of ALL and establish methylation and expression of ASPP1 as independent prognostic factors for patients with ALL. Our study also indicates that ASPP1 expression is at least partially regulated by epigenetic mechanisms such as gene promoter methylation and supports a role for ASPP members in the pathogenesis of ALL as a means by which ALL cells can escape apoptosis despite the presence of wild-type p53.
Material and methods

Cell lines
We studied seven ALL-derived cell lines (TOM-1, MY, NALM-20, LOUCY, TANOUE, JOURKAT and MOLT-4), five chronic myeloid leukemia (CML) (BV173, TCC-S, KU812, KYO-1, K562), 30 breast cancer-derived cell lines and 69 lung carcinoma-derived cell lines (see Supplementary information for description). All cell lines were maintained in culture in the corresponding media until harvested for DNA and RNA extraction.
Patients and samples
Bone marrow was obtained from 180 consecutive patients (110 male; 70 female) who were diagnosed with de novo ALL between January 1990 and December 2002 after informed consent had been obtained from the patient or the patient's guardians. The median age at diagnosis of the study population was 14 years (range, 0.5-82 years). Of these patients, 88 were children (median age 5 years; range 0.5-14 years) and 92 adult ALL (median age 29 years; range 15-82 years). Diagnosis was established according to standard morphologic, cytochemical and immunophenotypic criteria. Patients were studied at the time of initial diagnosis; were riskstratified according to the therapeutic protocol, which was always based on recognized prognostic features (including cytogenetics); and were entered in ALL protocols of the PETHEMA Spanish study group. For statistical analyses, children were also grouped according to the National Cancer Institute (NCI) risk-classification criteria (Smith et al., 1996) . The specific PETHEMA ALL treatment protocols in which these patients entered included ALL-89 (between 1990 and 1993; n ¼ 50) and ALL-93 (between 1993 and 2002; n ¼ 130) . The design and results of these studies have been reported previously (Ribera et al., 1998 (Ribera et al., , 2002 Ortega et al., 2001) . A total of 66 patients relapsed. In all, 27 patients received stem cell transplantation (seven autologous, 20 allogeneic) in the first (n ¼ 10) or second complete remission (CR) (n ¼ 17). There are 100 patients currently alive. Clinical characteristics of the patients are listed in Table 1 .
Quantitative real-time PCR (Q-RT-PCR)
Total RNA was extracted from mononuclear marrow cells or cell lines with Ultraspec (Biotecx, Houston, TX, USA) following the manufacturer's instructions. Reverse transcription was performed on 1 mg of total RNA, after heating at 701C for 5 min, with random hexamers as reaction primers. The reaction was carried out at 421C for 45 min in the presence of 12 U Avian Myeloblastosis virus reverse transcriptase (Boehringer-Mannhein, Germany). Q-RT-PCR was performed in a rapid fluorescent thermal cycler with three-color fluorescence monitoring capability (LightCycler, Roche Molecular Biochemicals, Mannheim, Germany), using 1 ml of cDNA in 20 ml reaction volume with 0.4 mmol/l of each primer, and 2 ml of 10 Â LightCycler FastStar DNA Master SYBR Green I (Roche Molecular Biochemicals, Mannheim, Germany). The final Mg 2 þ concentration in the reaction mixture was adjusted to 3.5 mmol/l. Primer set was specific for the ASPP1 (Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 13B (PPP1R13B), mRNA, GeneBank: NM_015316; sense, 5 0 -TTGTCCTCTCATTGCACG-3 0 ; antisense, 5 0 -AACTTACCCTCTCAGAGC-3 0 ), ASPP2 (tumor protein p53 binding protein, 2 (TP53BP2), mRNA, GeneBank: NM_005426; sense, 5 0 -GTGCTGCCTCATGTAACA AC-3 0 ; antisense, 5 0 -TATGCCCATCTTCTCCTGAAC-3 0 ) or iASPP (PPP1R13L, mRNA, GeneBank: NM_006663; sense, 5 0 -AGAGAGCGTACACTGC-3 0 ; antisense, 5 0 -GCAACGAC ACAGTCATC-3 0 ). The following program conditions were applied for Q-RT-PCR running: denaturation program, consisting in one cycle at 951C for 8 min; amplification program, consisting in 45 cycles at 951C for 5 s, 601C for 10 s and 721C for 15 s; melting program, one cycle at 951C for 0 s, 401C for 60 s and 901C for 0 s; and cooling program, one cycle at 401C for 60 s. The temperature transition rate was 201C/s, except in the melting program, which was 0.41C/s between 40 and 901C.
Amplification of ABL1 gene transcripts was performed to assess RNA integrity and as a reference gene (forward, 5 0 -CCCAACCTTTTCGTTGCACTGT-3 0 ; reverse, 5 0 -CGGCTC TCGGAGGAGACGTAGA-3 0 ). It was amplified in the same run and following the same procedure described above for ASPP1. In order to reduce the variation between different assays and samples, a procedure based on the relative quantification of target genes vs their controls in relation to the reference gene was used. . DCp corresponds to the difference between control Cp and sample Cp, either for the target or for the reference genes. The selected control was a bone marrow specimen from a healthy donor and was considered as 100% expression. Occasionally, equal amounts of PCR products were separated on a 2% agarose gel, stained ASPP1 expression and regulation in ALL X Agirre et al with ethidium bromide and visualized under UV light. Similar procedures were employed for analyzing ASPP2 and iASPP expression.
To determine the cutoff point for abnormal ASPP1 expression in ALL samples, the N ASPP1 value was determined in 20 bone marrow samples from healthy donors. The N ASPP1 value for ASPP1 falls between 107 and 86% (mean: 9376.6%). A N ASPP1 value below 60% (determined as the mean minor 5 s.d.) was chosen to define underexpression of ASPP1 in ALL RNA samples. Following the same experiment, a value below 60% was also considered to define underexpression of both ASPP2 and iASPP genes.
Methylation-specific PCR DNA of all cell lines and primary tumors was extracted using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). We used an methylation-specific PCR (MSP) technique to analyze and determine the methylation status of ASPP1 and ASPP2 promoter region (GeneBank: NM 015316 and NM 005426). MSP is based on a bisulfite treatment of the DNA that modifies unmethylated but not methylated cytosines into uracils. Subsequent PCR using primers specific to sequences corresponding to either methylated or unmethylated DNA were performed. 1 mg of genomic DNA was treated and modified using the CpGenomict DNA Modification Kit (Intergen Company, Purchase, NY, USA). Bone marrow DNA from healthy donors was used as a negative control and human male genomic DNA universally methylated for all genes (Intergen Company, Purchase, NY, USA) was used as a positive control for methylation-specific assays. PCR reactions for ASPP1-MSP and ASPP2-MSP were carried out in a total volume of 25 ml, using 3 ml of modified DNA, 1 U AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA, USA), 1.5 mM MgCl 2 , 0.2 mM dNTPs and 50 pmol of each primer. For ASPP1-MSP, ASPP1-1 (5 0 -AAGTAGGTGTTA GTTAAGGGCGTC-3 0 ) and ASPP1-2 (5 0 -ACCGACTATAA ACCGAAAACGT-3 0 ) primers were used for the methylated reaction, which amplify a 205 bp product and ASPP1-3 (5 0 -AA GTAGGTGTTAGTTAAGGGTGTTG-3 0 ) and ASPP1-4 (5 0 -AAACCAACTATAAACCAAAAACATC-3 0 ) primers for the unmethylated reaction, which amplify a 207 bp product. For ASPP2-MSP were used ASPP2-1 (5 0 -ATTTTGTTTAC GCGTTTAACGTC-3 0 ) and ASPP2-2 (5 0 -GAAACAATTAA AAAACCGCG-3 0 ) primers for the methylated reaction, which amplify a 164 bp product and ASPP2-3 (5 0 -ATTTTGTTTA TGTGTTTAATGTTGG-3 0 ) and ASPP2-4 (5 0 -CAAAACA ATTAAAAAACCACACC-3 0 ) primers for the unmethylated reaction, which amplify a 165 bp product. PCR conditions for ASPP1-1/ASPP1-2 and ASPP2-1/ASPP2-2 primers were 941C for 10 min, followed by 35 cycles at 941C for 1 min, 591C for 1 min and 721C for 1 min; ASPP1-3/ASPP1-4 and ASPP2-3/ASPP2-4 primers conditions were 941C for 10 min, followed by 35 cycles at 941C for 1 min, 551C for 1 min and 721C for 1 min. The final extension was at 721C for 10 min in both cases. MSP products were separated on a 2% agarose gel, stained with ethidium bromide and visualized under UV light. Results were confirmed by repeating bisulfite treatment and MSP assays for all samples. Treatment with a demethylating agent 5-Aza-2 0 -deoxycytidine ALL-derived TOM-1, NALM-20 and MY cell lines were grown at a density of 600 000 cells/ml in 25 cm 2 flasks with 10 ml of RPMI 1640 medium supplemented with 20% fetal bovine serum and maintained at 371C in a humid atmosphere containing 5% CO2. Each cell line was treated with 2 and 4 mM of 5-Aza-2 0 -deoxycytidine (Sigma-Aldrich, Steinheim, Germany) for 4 days. After treatment, cells were washed in PBS, pelleted by centrifugation at 1500 r.p.m. during 5 min and used for genomic DNA and RNA isolation. DNA was extracted using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) and total RNA using Rneasy s Mini Kit (Qiagen, Hilden, Germany). Of total RNA, 1 mg was used for cDNA synthesis using SuperScriptt II RNase H-RT (Invitrogen Life Technologies, Paisley, UK) with random hexamers.
MSP product sequencing
FISH analysis
Detection of ASPP1 and TP53 deletion was performed by FISH in ALL-derived TOM-1, NALM-20, MY, LOUCY and TANOUE cell lines. FISH analysis for ASPP1 was performed with RP11-73M18 BAC clone that covers the ASPP1 gene, RP11-600F24 BAC clone centromeric to ASPP1 that covers the MARK3 gene and an alphoide probe that covers the chromosome 14 and 22 centromeres. TP53 FISH analysis was performed with RPCI-11 199F11 BAC clone (located on 17p13.1) and one alphoide probe that covers the chromosome 17 centromere. These clones were identified by the Human Genome Project Working Draft of the University of California at Santa Cruz (http://genome.ucsc.edu) and by the National Center for Biotechnology Information (http://www.ncbi.nlm.-nih.gov). The clones were obtained from the Children's Hospital Oakland Research Institute (http://www.chori.org/ bacpac/home.htm). All DNA probes were prepared with a QIAprep s Spin Miniprep Kit (Qiagen, Hilden, Germany). For ASPP1 FISH analysis, RP11-73M18 BAC DNA was labeled with Spectrum Orange s -dUTP, RP11-600F24 with Spectrum Green s -dUTP and alphoide DNA with diethylaminocoumarin-5-dUTP (DEAC) (Vysis, Downers Grove, IL, USA) by nick translation with a Nick Translation Mix (Roche Molecular Biochemicals, Mannheim, Germany). For TP53, RPCI-11 199F11 BAC DNA was labeled with Spectrum Orange s -dUTP and alphoide DNA with Spectrum Green s -dUTP (Vysis, Downers Grove, IL, USA). Chromosomes were identified using counterstaining with 4 0 ,6-diamidino-2-phenylindoledihydrochloride and 1,4-diazabicicle-(2.2.2)-octane (DAPI-Antifade) (Appligene Oncor, Ilkirch, France). The slides were analyzed with an Axioplan 2 Imaging fluorescence microscope (Zeiss, Go¨ttingen, Germany) and digital images were collected using a CCD camera and analyzed by the in situ imaging system 3.4.0. software (Metasystem, Altlussheim, Germany).
Analysis of TP53 mutations and methylation
We analyzed exons 5-8 of TP53 gene by DGGE, a highly sensitive technique to scan for mutations, and exons 1-4 and 9-11 of TP53 by direct sequencing in ALL-derived TOM-1, NALM-20, MY, LOUCY and TANOUE cell lines. Primer sequences, PCR and DGGE conditions used for each TP53 exon were those described by Agirre et al. (2002) for exon 1-5 ASPP1 expression and regulation in ALL X Agirre et al and 9-11, Borresen et al. (1991) for exons 7 and 8 and by Hamelin et al. (1993) for exon 6. Negative controls (wild-type samples) and positive controls (known mutants) were included in each experiment. Fragments showing an altered migration pattern with respect to the wild-type control in a DGGE analysis were subjected again to the complete procedure in order to confirm the initial results. Those fragments with at least two repeated aberrant patterns were purified from the initial PCR reactions and both strands were sequenced with fluorescence labeled chain terminators in an ABIPRISM 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
For methylation analysis, genomic DNA was completely digested with methylation-sensitive restriction enzymes Hpa II (for CpG dinucleotides) and Eco RII (for CCWGG motifs), and then amplified by PCR . In these assays, unmethylated sites are digested and cannot be amplified, whereas the presence of a methylated cytosine prevents digestion and results in successful amplification. Digestion controls were performed with Msp I and BstN I, which recognize the same sites as Hpa II and Eco RII, respectively, but are methylation-insensitive. This analysis was realized in ALL-derived TOM-1, NALM-20, MY, LOUCY and TANOUE cell lines and in a positive control. Digestion and PCR conditions used were as described .
Statistical analysis
P-values to compare the continuous variables between groups of patients were two-tailed and based on the Wilcoxon rank sum test. P-values for dichotomous variables were based on the Fisher exact test. The remaining P-values were based on the Pearson w 2 . Overall survival (OS) was measured from the day of diagnosis until death from any cause and was only censored for patients known to be alive at last contact. Disease-free survival (DFS) was measured from the day that complete response (CR) was established until either relapse or death without relapse, and it was only censored for patients who were alive without evidence of relapse at the last followup. Distributions of OS and DFS curves were estimated by the method of Kaplan and Meier with 95% confidence intervals calculated using Greenwood's formula. Comparisons of OS or DFS between groups were based on the log-rank test. Comparisons adjusted for significant prognostic factors were based on Cox regression models and hazard regression models. All relapse and survival data were updated on March 31, 2005 and all follow-up data were censored at this point.
